Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
Newsoara BioPharma Co., Ltd. and vTv Therapeutics LLC have expanded their strategic collaboration, with Newsoara...
vTv Therapeutics
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...